Clinical Trial

A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2023 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-10; most recent amendment 2023-11-03.
Status change: Not Yet Recruiting → Recruiting 2023-08-21
Trial Details
NCT Number NCT05866692
Lead Sponsor TYK Medicines, Inc
Conditions Solid Tumor, Adult
Enrollment 156 participants
Start Date 2023-08-17
Primary Completion 2025-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2023-11-07